Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
Supports ACE inhibitor or calcium antagonist use to slow hypertensive renal damage; leaves open optimal regimens pending contemporary randomized data.
The kidney may contribute to and be damaged by hypertension. Evidence from studies of renal transplant recipients and familial studies suggests a genetic component for the occurrence of hypertension and nephrosclerosis. Glomerular injury may result from glomerular hypertension caused by loss of autoregulation and afferent renal vasodilatation. Glomerular injury may be mediated by injury to endothelial cells, which, having lost their thromboresistance, may initiate intravascular coagulation and alter the balance between endothelin and endothelium-derived relaxing factor. Increased transit of protein-laden fluid into the mesangial space also may mediate hypertensive nephrosclerosis. Several studies have provided encouraging evidence that antihypertensive therapy, particularly with angiotensin-converting enzyme inhibitors or calcium antagonists, can slow the progression of renal damage.
No takes yet. Share an insight, caveat, or question.
Ritz et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: